Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01230957
Recruitment Status : Completed
First Posted : October 29, 2010
Last Update Posted : July 18, 2018
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )

Brief Summary:

This study will further evaluate the ACAM-CDIFF™ vaccine in a population of middle-aged to elderly individuals at risk of exposure to Clostridium difficile because of impending hospitalization or residence in a care facility.

Primary Objectives:

  • To describe the safety profile of subjects in each of the study groups.
  • To describe the immune responses elicited by toxoid A and toxoid B of subjects in each of the study groups.

Observational Objective:

  • To describe the occurrence of first-time Clostridium difficile infection (CDI) episodes.

Condition or disease Intervention/treatment Phase
Clostridium Difficile Infection Diarrhea Biological: Clostridium difficile toxoids A and B (Low-dose with adjuvant) Biological: Clostridium difficile toxoids A and B (Low-dose without adjuvant) Biological: Clostridium difficile toxoids A and B (high-dose with adjuvant) Biological: Clostridium difficile toxoids A and B (high-dose without adjuvant) Biological: Placebo: 0.9% normal saline Phase 2

Detailed Description:

Participants will receive 3 doses of either one of 4 different formulations of ACAM-CDIFF™ vaccine or placebo, on one of 3 different schedules. The trial will have 2 stages. Stage I will test 4 different formulations of ACAM-CDIFF™ vaccine. Stage II will explore different vaccination schedules using one of these formulations.

Participants will be followed up for safety and immunogenicity; stool samples will also be provided in case of diarrhea.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 650 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Study Start Date : October 2010
Actual Primary Completion Date : November 2012
Actual Study Completion Date : March 2013

Arm Intervention/treatment
Experimental: Group 1
Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
Biological: Clostridium difficile toxoids A and B (Low-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Other Name: ACAM-CDIFF™ vaccine

Experimental: Group 2
Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
Biological: Clostridium difficile toxoids A and B (Low-dose without adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Other Name: ACAM-CDIFF™ vaccine

Experimental: Group 3
Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
Biological: Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Other Name: ACAM-CDIFF™ vaccine

Experimental: Group 4
Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
Biological: Clostridium difficile toxoids A and B (high-dose without adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Other Name: ACAM-CDIFF™ vaccine

Placebo Comparator: Group 5
Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
Biological: Placebo: 0.9% normal saline
0.5 mL, Intramuscular on Days 0, 7, and 30
Other Name: 0.9% normal saline

Experimental: Group 6
Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
Biological: Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 180
Other Name: ACAM-CDIFF™ vaccine

Experimental: Group 7
Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.
Biological: Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 30, and 180
Other Name: ACAM-CDIFF™ vaccine




Primary Outcome Measures :
  1. Information concerning the safety profile in terms of solicited and unsolicited reactions in participants following vaccination with ACAM-CDIFF™ Vaccine. [ Time Frame: 6 days after each vaccination and up to 6 months post-vaccination 3 ]
  2. Serum antitoxin IgG concentrations to Clostridium difficile toxins A and B in participants vaccinated with ACAM-CDIFF™. [ Time Frame: Up to 6 months post-vaccination 3 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Aged 40 to 75 years on the day of inclusion
  • Informed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all trial procedures
  • For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination
  • At risk for developing Clostridium difficile infection during the trial because of impending elective surgery or hospitalization within 60 days of enrollment, or current or impending residence in a long-term care facility or rehabilitation facility.

Exclusion Criteria:

  • Known pregnancy, or a positive urine pregnancy test
  • Currently breastfeeding a child
  • Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
  • Planned participation in another clinical trial during the present trial period
  • Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza (seasonal or pandemic) and pneumococcal vaccine
  • Planned receipt of any vaccine in the 4 weeks following any trial vaccination, except for influenza (seasonal or pandemic) and pneumococcal vaccines
  • Previous vaccination against Clostridium difficile with either the trial vaccine or another vaccine
  • Current or prior Clostridium difficile infection (CDI) episode
  • Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Self-reported seropositivity for Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C
  • Anticipated or current receipt of kidney dialysis treatment
  • Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances
  • Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
  • Identified as a study site employee who is involved in the protocol and may have direct access to trial-related data
  • Subjects who have any history of intestinal diverticular bleeding
  • Subjects who have had surgery within the past three months for gastrointestinal (GI) malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01230957


  Show 30 Study Locations
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
Investigators
Layout table for investigator information
Study Director: Medical Director Sanofi Pasteur Inc.

Publications of Results:
Layout table for additonal information
Responsible Party: Sanofi Pasteur, a Sanofi Company
ClinicalTrials.gov Identifier: NCT01230957     History of Changes
Other Study ID Numbers: H-030-012
UTN: U1111-1114-3917 ( Other Identifier: WHO )
First Posted: October 29, 2010    Key Record Dates
Last Update Posted: July 18, 2018
Last Verified: July 2018
Keywords provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):
Clostridium difficile infection
Diarrhea
Pseudomembranous colitis
Clostridium Difficile Toxoid Vaccine
ACAM-CDIFF™ vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Clostridium Infections
Diarrhea
Signs and Symptoms, Digestive
Signs and Symptoms
Gram-Positive Bacterial Infections
Bacterial Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs